IRB #

IRB00011227

Title

VAPORHCS/OHSU J: A Phase I/II Trial of Concurrent Chemohormonal Therapy Using Enzalutamide (MDV-3100) and Cabazitaxel in Patients with Metastatic Castration Resistant Prostate Cancer

Principal Investigator

Julie Graff

Study Purpose

The purpose of this study is to determine the side effects (both good and bad) of the combination of cabazitaxel (Jevtana) and enzalutamide (XTANDI), and to determine if the combination is effective in the treatment of Castration Resistant Prostate Cancer (CRPC).

Medical Condition(s)

Castration Resistant Prostate Cancer (CRPC)

Eligibility Criteria

-Currently progressing despite androgen suppression therapy
-No prior enzalutamide, cabazitaxel, or other chemotherapy for CRPC
-No history of seizures or current treatment with medications that lower the seizure threshold

Age Range

18 - 110

Healthy Volunteers Needed

No

Duration of Participation

Active treatment will continue until cancer stops responding to the study therapy; at least 12 weeks and up to 2 years. Participants will be followed for long-term status for up to 5 years.

Minors Included

No

Contact

Knight Cancer Institute Clinical trials information line: Phone 503-494-1080 or trials@ohsu.edu

Sponsor

Oregon Health & Science University

Recruitment End

12/30/2019

Compensation Provided

No


Go Back